about
Strategies for preventing calcium oxalate stonesRandomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosisThe role of continuous renal replacement therapy in the treatment of poisoningMedical management of kidney stones: AUA guidelineEvidence for inheritance of medullary sponge kidneyHypothesis: Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stonesA pilot study of the effect of sodium thiosulfate on urinary lithogenicity and associated metabolic acid load in non-stone formers and stone formers with hypercalciuriaInterpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.Metabolic evaluation of first-time and recurrent stone formers.A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.Prevention of recurrent nephrolithiasis.Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy.Use of a probiotic to decrease enteric hyperoxaluria.The normal saline ceremony.Hereditary causes of kidney stones and chronic kidney diseaseProgressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall proteinEffect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine studyCrystal growth inhibitors for the prevention of L-cystine kidney stones through molecular designTreatment of pregabalin toxicity by hemodialysis in a patient with kidney failure.Ichthyotoxic ARF after fish gallbladder ingestion: a large case series from Vietnam.Facilitating the transition from physiology to hospital wards through an interdisciplinary case study of septic shockThe association of nephrolithiasis with cystic fibrosis.Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes.The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young AdultsMetabolic and metagenomic outcomes from early-life pulsed antibiotic treatmentNovel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse modelUpdate on cystinuria.Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formersTreatment of calcium nephrolithiasis in the patient with hyperuricosuria.Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.Urine proteomic analysis in cystinuric children with renal stones.The role of the microbiome in kidney stone formation.The Clinical Impact of Accurate Cystine Calculi Characterization Using Dual-Energy Computed Tomography.The exposome for kidney stones.Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis.The association of nephrolithiasis with hypertension and obesity: a review.Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population HealthAsymptomatic nephrolithiasis detected by ultrasound.
P50
Q24545733-DC9EFEBC-C159-4D6F-9729-90304EBEDA74Q28199574-DEE86993-DD1D-4DEC-A28A-2F2AFEDBF9DEQ28200475-561C6B8D-D7CF-4EAA-8760-B172B87CC79CQ28240681-093A1295-8F0D-40EB-83E5-FE81E0203446Q28284592-391C4870-E5DA-4FE9-B3FA-3027C78DF8F6Q28394024-5B30239C-96D6-44C6-8291-AAAD80F57F27Q28486066-B9E11F0F-B096-457B-81A5-9A5370B035B6Q33371531-60621122-8C3D-47A8-A477-32EBEC1F9427Q33737379-2F3A32C3-839F-4D79-95D0-728623A5EC1CQ33770038-39972180-B881-41AF-9F9E-80F5EDBDCDCCQ33791970-2153DF40-136B-4AE7-A6FB-C28C55985928Q33954138-5B32089F-2155-4E52-B555-CD1CD16663FAQ33989387-04DB17CD-17B7-4781-B2DB-AC9C334D5911Q34025867-F7A498A4-3198-4230-BF78-D3F7D4719C89Q34066169-AF817D97-B626-4327-8B6C-E5FDB6BB61F5Q34149642-228A4290-84A4-4678-A3B9-5E34EC7CC543Q34582863-49B5335F-6647-49D7-AE73-AED2E532699CQ34610179-3CFB5B93-9A17-4EAF-9AA9-956C45A664E6Q34624373-90AA6853-86FE-4221-8ADD-DA23A0661B97Q34984708-B95B4BF8-0F86-46F0-9BF1-42444873BC27Q35033818-01485EF7-5940-4555-9274-998E2500F933Q35146000-20708914-F0D5-489E-8C99-6605E8B12AC7Q35164282-BC5DF55A-9D2C-43B7-9F8C-762930EB0B6AQ35165543-AA380707-A5E5-43C9-9FF6-1FBE2D917D3BQ35534406-E89FC93D-7AD5-4E45-A594-3CF94EF37C52Q35751434-A8890956-9D6C-498B-9513-9E575BD467F0Q35816663-A4F96B57-A7BE-4773-91BB-4533C1CF136AQ35838598-7B6EB8F5-F4FB-4EBD-BA85-D89555CD7872Q35887884-3ACADF78-CDA3-44BC-8FD3-61F3B5E4FF6FQ35887949-6357A313-5344-4AAB-A0CC-F652085F605DQ35888115-7D4A2810-CE2D-4B02-A148-969B71216046Q35899117-154DE73B-B15E-4127-A4A8-B8DEFC347DBFQ35967762-0C193FB0-BA8A-4D37-82F7-DD342EAE659FQ36193540-2F0B7C80-7E92-42E1-A589-A9D75EAC8167Q36356515-1FF280CD-B24F-48A4-A640-87F91424744BQ36501358-B76C6B02-C972-45CA-929D-5CE0CBCC4966Q36768914-C1292759-8DA8-450B-BCB8-17E919F6827BQ37064844-9830DCEB-19FC-43C7-9F01-9E444DAAE10DQ37070036-3769AE1F-2E11-4AB8-8C10-0609B88F9DE7Q37123160-6F0DEAEE-6647-4328-B1B8-5ED4B1ADA663
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David S Goldfarb
@ast
David S Goldfarb
@en
David S Goldfarb
@es
David S Goldfarb
@nl
David S Goldfarb
@sl
type
label
David S Goldfarb
@ast
David S Goldfarb
@en
David S Goldfarb
@es
David S Goldfarb
@nl
David S Goldfarb
@sl
prefLabel
David S Goldfarb
@ast
David S Goldfarb
@en
David S Goldfarb
@es
David S Goldfarb
@nl
David S Goldfarb
@sl
P106
P2038
David_Goldfarb
P21
P31
P496
0000-0002-9215-1273